Search

Search Constraints

You searched for: Author/Creator Lord, Brian

Search Results

1. Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia. (December 2018)

2. Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia. (December 2018)

3. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ‐47965567. (17th September 2013)

4. Discovery and SAR studies of 2-alkyl-3-phenyl-2, 4, 5, 6, 7, 8-hexahydropyrazolo[3, 4-d]azepines as 5-HT7/2 inhibitors leading to the identification of a clinical candidate. (1st January 2021)

5. Preclinical characterization of substituted 6, 7-dihydro-[1, 2, 4]triazolo[4, 3-a]pyrazin-8(5H)-one P2X7 receptor antagonists. Issue 2 (15th January 2016)

6. P2X7 receptor antagonism reduces the severity of spontaneous seizures in a chronic model of temporal lobe epilepsy. (June 2016)

7. P2X7 receptor antagonism reduces the severity of spontaneous seizures in a chronic model of temporal lobe epilepsy. (June 2016)

8. Novel methyl substituted 1-(5, 6-dihydro-[1, 2, 4]triazolo[4, 3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists. Issue 16 (15th August 2015)

9. Novel methyl substituted 1-(5, 6-dihydro-[1, 2, 4]triazolo[4, 3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists. Issue 16 (15th August 2015)